<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002040</url>
  </required_header>
  <id_info>
    <org_study_id>H09-02820</org_study_id>
    <nct_id>NCT01002040</nct_id>
  </id_info>
  <brief_title>Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV</brief_title>
  <official_title>PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults With Human Immunodeficiency Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness (immune response) to a
      licensed H1N12009 influenza vaccine in HIV-infected adults. The study will enroll 150 adults
      (ages 20-59 years). Participants will be randomized into 2 groups and will receive either one
      dose or two doses of a licensed H1N1 vaccine. Study procedures include: medical history,
      blood samples and completing a memory aid. Participants will be involved in study related
      procedures for approximately 6 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the first wave of the H1N12009 pandemic in Canada, adults with immune deficiency were
      more likely to die with severe infections than were other Canadians. Of 76 deaths attributed
      to date to this new virus, 37% occurred in persons with immune system compromise. Adults with
      human immunodeficiency virus (HIV) infection constitute a significant proportion of the
      at-risk population with over 56,000 affected individuals. Most such individuals retain some
      capacity to respond to influenza vaccination. The dosing regimen for the pandemic vaccine
      will be based on limited studies in the general population, leaving open the question of
      whether HIV-infected persons can respond satisfactorily to the recommended dosing.
      Availability of an adjuvanted formulation of the pandemic vaccine may improve responsiveness
      but two doses may be required for the best possible response. Thus it would be optimal to
      evaluate the safety and immunogenicity of the pandemic vaccine among the earliest
      HIV-infected persons to receive it, to inform the subsequent vaccination of others.

      The objectives of this study are three-fold:

        1. To evaluate the safety and immunogenicity of H1N12009 influenza vaccine in a convenience
           sample of adults with HIV infection.

        2. To compare immune responses of subjects randomized to receive either one or two doses of
           adjuvanted vaccine to identify the optimal regimen.

        3. To complete this evaluation soon after the pandemic vaccine becomes available so as to
           inform the subsequent use of the vaccine in HIV-infected persons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs) for days 0-6 after each vaccination</measure>
    <time_frame>Day 7 and Day 21 post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) and other significant health events up to 21 days after each vaccination</measure>
    <time_frame>Day 7 and Day 21 post vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Comparison of baseline and post-immunization antibody titres</measure>
    <time_frame>Day 21 post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>HIV Infections</condition>
  <condition>H1N1 Influenza</condition>
  <arm_group>
    <arm_group_label>One Dose Influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arepanrix H1N1 Influenza vaccine (one dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two Doses Influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Arepanrix</intervention_name>
    <description>Group A receives one dose of Arepanrix</description>
    <arm_group_label>One Dose Influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Arepanrix</intervention_name>
    <description>Group B receives 2 doses of Arepanrix 3 weeks apart</description>
    <arm_group_label>Two Doses Influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laboratory-confirmed HIV

          -  Written informed consent

          -  Adults 20-59 years of age

        Exclusion Criteria:

          -  Allergies to eggs, thimerosal or gentamicin sulphate

          -  Life-threatening reaction to previous Flu vaccine

          -  Bleeding disorder

          -  Pregnancy

          -  Receipt of blood or blood products in past 3 months

          -  Chronic illness

          -  Previous lab-confirmed H1N12009 infection

          -  Receipt of any non-study H1N12009 or Seasonal Influenza vaccine for 2009/10
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Scheifele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Curtis Cooper, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Ottawa / Ottawa Hospital Research Institute,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Klein, MD</last_name>
    <role>Study Director</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Ward, MD</last_name>
    <role>Study Director</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Walmsley, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison McGeer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hasse, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shelly McNeil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa / Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>vaccine,</keyword>
  <keyword>H1N1</keyword>
  <keyword>influenza</keyword>
  <keyword>H1N1 Influenza vaccine</keyword>
  <keyword>Arepanrix</keyword>
  <keyword>Pandemic</keyword>
  <keyword>H1N1 2009 Influenza</keyword>
  <keyword>HIV preventive vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

